Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 96

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 96
---
 Requirement. On November 7, 2024, we
were formally notified that the Panel determined that we had regained compliance with the Minimum Bid Price Requirement. We remain subject
to a discretionary panel monitor through February 24, 2025, and we are required to provide prompt notification during this exception period
of any significant events that occur during this time that may affect our compliance with NASDAQ requirements.

While we have regained compliance
with all applicable requirements for continued listing on the NASDAQ Capital Market, we cannot assure you that we will remain in compliance
with all applicable requirements for continued listing on the NASDAQ Capital Market. If, in the future, we fail to sustain compliance
with all applicable requirements for continued listing on NASDAQ, including during the one-year monitoring period, our Depositary Shares
may be subject to delisting by NASDAQ. This could inhibit the ability of our holders of Depositary Shares to trade their shares in the
open market, thereby severely limiting the liquidity of such shares. Although holders may be able to trade their shares of Depositary
Shares on the over-the-counter market, there can be no assurance that this would occur. Further, the over-the-counter market provides
significantly less liquidity than NASDAQ and other national securities exchanges, is thinly traded and highly volatile, has fewer market
makers and is not followed by analysts. As a result, your ability to trade or obtain quotations for these securities may be more limited
than if they were quoted on NASDAQ or other national securities exchanges.

The price of our Depositary Shares may be volatile.

The trading price of our Depositary
Shares in the United States has fluctuated, and is likely to continue to fluctuate, substantially in response to various factors, some
of which are beyond our control, including limited trading volume. The stock market in general, and the market for pharmaceutical and
biotechnology stocks in particular, have experienced extreme volatility that has often been unrelated to the operating performance of
these companies. As a result of this volatility, investors may not be able to sell their Depositary Shares at or above the price paid
for the Depositary Shares. In addition, there is no current market for our Ordinary Shares and we do not expect to list our Ordinary Shares
on any exchange or have them quoted for trading on any over-the-counter trading system in the foreseeable future.

In addition to the factors
discussed in this “Risk Factors” section, the factors that could cause volatility in the market price of each Depositary
Share include